Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

1.680 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aytu Biopharma Inc

< Previous 1 2 3 Next >
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Via ACCESSWIRE
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
Via ACCESSWIRE
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
Via ACCESSWIRE
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
Via ACCESSWIRE
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
Via ACCESSWIRE
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row
Via ACCESSWIRE
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
Via ACCESSWIRE
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan
Via ACCESSWIRE
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
Via ACCESSWIRE
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
Via ACCESSWIRE
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
Via ACCESSWIRE
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
Via ACCESSWIRE
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions
Via ACCESSWIRE
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue
Via ACCESSWIRE
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
Via ACCESSWIRE
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
Via ACCESSWIRE
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
Via ACCESSWIRE
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Via ACCESSWIRE
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
Via ACCESSWIRE
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
Via ACCESSWIRE
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
Via ACCESSWIRE
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs
Via ACCESSWIRE
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
Via ACCESSWIRE
Aytu BioPharma to Participate in September 2022 Investor Conferences
Via ACCESSWIRE
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
Via ACCESSWIRE
Aytu BioPharma Announces Pricing of Public Offering
Via ACCESSWIRE
Aytu BioPharma Announces Launch of Public Offering
Via ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.